Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CCL2 | P13500 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25038692 | 0.74 | BRD4 (0.36) | HTR5ABRD4CCL2HTR2A | |
| SCHEMBL28445883 | 0.71 | MAOA (0.33) | HTR2A | |
| SCHEMBL6045293 | 0.71 | HTR2A (0.35) | HTR2A | |
| SCHEMBL24596781 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL7724483 | 0.70 | KDM1A (0.36) | HTR2A | |
| SCHEMBL11825016 | 0.69 | — | — | |
| SCHEMBL8157017 | 0.68 | BRD4 (0.38) | HTR5ABRD4CCL2HTR2A | |
| SCHEMBL23513879 | 0.68 | EDNRA (0.32) | — | |
| SCHEMBL23264409 | 0.67 | KDM1A (0.31) | — | |
| SCHEMBL3998927 | 0.67 | BRD4 (0.30) | BRD4CCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240224789-A1 | IONIC COMPOUND AND APPLICATION THEREOF, PEROVSKITE PRECURSOR SOLUTION, PEROVSKITE MATERIAL, SOLAR CELL, AND ELECTRIC APPARATUS | CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-118043309-A | Ionic compound and application thereof, perovskite precursor solution, perovskite material, solar cell and electricity utilization device | 宁德时代新能源科技股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4321505-A1 | IONIC COMPOUND AND USE THEREOF, PEROVSKITE PRECURSOR SOLUTION, PEROVSKITE MATERIAL, SOLAR CELL, AND ELECTRICAL DEVICE | Contemporary Amperex Technology Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023240629-A1 | IONIC COMPOUND AND USE THEREOF, PEROVSKITE PRECURSOR SOLUTION, PEROVSKITE MATERIAL, SOLAR CELL, AND ELECTRICAL DEVICE | 宁德时代新能源科技股份有限公司 | 2023-12-21 | — | — | WO | disclosed |
| EP-4234566-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI Shenzhen (CN) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022083686-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | 深圳华大生命科学研究院 | 2022-04-28 | — | — | WO | disclosed |
| US-9780310-B2 | Heterocyclic compound for organic electroluminescent device and its application | TOSOH CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9780310-B2 | Heterocyclic compound for organic electroluminescent device and its application | TOSOH CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | TOSOH CORPORATION (JP) | 2016-02-25 | — | — | US | disclosed |
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | TOSOH CORPORATION (JP) | 2016-02-25 | — | — | US | disclosed |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2013121439-A2 | PROCESS FOR GARENOXACIN MESYLATE | GLENMARK GENERICS LIMITED (IN) | 2013-08-22 | — | — | WO | disclosed |
| EP-0885186-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | Dr. Karl Thomae GmbH (DE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997019911-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1997-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | AOC2, AZI2, KCNH2 | HTR5A 554/4885BRD4 116/4885CCL2 2953/4885 |
| US-20240224789-A1 | IONIC COMPOUND AND APPLICATION THEREOF, PEROVSKITE PRECURSOR SOLUTION, PEROVSKITE MATERIAL, SOLAR CELL, AND ELECTRIC APPARATUS | HCN2, HCN1, PIEZO1 | HTR5A 4624/4885BRD4 1144/4885CCL2 2805/4885 |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2C, ADRA2B | HTR5A 18/4885BRD4 522/4885CCL2 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.